

Certificate of Analysis for NR-52202

Acinetobacter baumannii, Strain MRSN 17493

Catalog No. NR-52202

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 17493 was isolated in 2013 from a human respiratory sample in the United States as part of a global surveillance program. A. baumannii, strain MRSN 17493 was deposited as multilocus sequence type (MLST) ST 632, resistant to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, colistin, gentamicin, imipenem, levofloxacin, meropenem, tetracycline, trimethoprim/sulfamethoxazole and tobramycin. NR-52202 was produced by inoculation of BEI Resources lot 70039048 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70055206 Manufacturing Date: 26AUG2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C ¹ 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility BBL™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Non-motile	Non-motile
VITEK® MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)
Antibiotic Susceptibility Profile ^{2,3}		
Amikacin	Resistant	Resistant (256 μg/mL)
Ampicillin/sulbactam	Resistant	Resistant (16 µg/mL)
Cefepime	Resistant	Resistant (24 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (32 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Tobramycin	Resistant	Resistant (≥ 16 µg/mL)
Tetracycline	Resistant	Resistant (≥ 16 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to A. baumannii, strain MRSN 17493 (GenBank: VHGN01000093.1)	100% sequence identity to A. baumannii, strain MRSN 17493 (GenBank: VHGN01000093.1)
Purity 7 days at 37°C in an aerobic atmosphere with 5% CO ₂ on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-52202

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

¹Growth at 44°C differentiates A. baumannii from A. calcoaceticus and A. pittii, which do not grow at 44°C.

Figure 1: Colony Morphology



/Sonia Bjorum Brower/
Sonia Bjorum Brower

03 APR 2023

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre™ GNX2F AST and E-test strips.